The health crisis is increasingly becoming a productivity crisis.
Brussels
Obesity and excess weight are costing European economies billions of euros every year, creating a financial burden comparable in some countries to major public spending categories such as housing or defense. A new analysis commissioned by the European pharmaceutical industry estimates that the annual economic impact ranges from 0.7 to 1.4 percent of national GDP across eight European countries. The figures move obesity beyond the conventional boundaries of public health. They present it as an increasingly significant economic and social challenge.
Germany carries the largest estimated financial burden, at approximately €55.2 billion annually, followed by the United Kingdom at €43.2 billion. Spain, Italy and France each face costs of around €20 billion a year, while Romania records the lowest total among the countries analyzed at about €2.5 billion. On a per capita basis, the estimated burden ranges from €131 in Romania to €662 in Germany. In Germany, Spain and Ireland, the economic impact associated with a high body mass index is already estimated to exceed national defense spending as a share of GDP.
The scale of the problem reflects rising prevalence. In 2024, approximately 26 percent of European adults were living with obesity, while another 30 percent were classified as overweight. Compared with 1990, the prevalence of overweight and obesity among adults has increased by 22 percent, while obesity alone has risen by more than 75 percent. Current projections suggest that the global burden could continue expanding significantly over the next decade.
The financial consequences extend far beyond direct medical treatment. Conditions associated with obesity include type 2 diabetes, cardiovascular disease, fatty liver disease, several cancers, neurological disorders and chronic respiratory illnesses. Across the eight countries examined, direct healthcare costs linked to excess weight were estimated at €100.4 billion. Additional losses come through absenteeism, reduced economic participation, informal care and premature mortality.
The human cost is equally significant. The report associates obesity and excess weight with approximately 278,000 deaths and the loss of eight million years of healthy life across the countries analyzed. Those figures underline why prevention, diagnosis and treatment increasingly have consequences for labor markets, productivity and the resilience of public healthcare systems.
The findings were commissioned by the European pharmaceutical industry, an important context when interpreting recommendations for expanded prevention and treatment. Even so, the economic scale identified raises a broader policy question. Europe is no longer confronting obesity solely as a medical condition. It is confronting a long term structural cost that increasingly reaches hospitals, workplaces, public budgets and economic growth.
Detrás de cada dato, la intención. / Behind every data point, the intention.